Low-Dose Micronized Indacaterol Maleate Dispersed on α-Lactose Monohydrate Carriers in Hard Capsule Dry Powder Inhalers

Commercial manufacture of single-entity indacaterol dry powder inhalation capsules is confined to orally inhaled dosage forms; oral swallowed tablets, oral granules, and injectable presentations are not established downstream commercial categories for this molecule because the active is developed for pulmonary delivery with low systemic oral bioavailability. The finished capsule fill mass is commonly targeted at 25 mg, yielding indacaterol maleate addition ratios of 0.30% w/w for the 75 µg labeled strength, 0.60% w/w for the 150 µg strength, and 1.20% w/w for the 300 µg strength, with label strength expressed as indacaterol free base and corrected for maleate salt stoichiometry. Micronization of the API is performed by spiral jet milling under nitrogen to a mass median aerodynamic diameter below 5 µm, because carrier-based dispersion in the lung requires a fine particle fraction that is incompatible with coarse API crystals. Downstream blending uses a low-shear tumble blender operated at 10–25 rpm for a residence window of 30–60 min; the blend is first passed through a 500 µm screen to disrupt pre-blend aggregates. Capsule filling on dosator-type equipment maintains a fill weight tolerance of ±5% at 25 mg; the process is monitored under 21 CFR 211.110 for in-process blend uniformity and under Ph. Eur. 2.9.40 for uniformity of dosage units. Aerodynamic quality is controlled according to Ph. Eur. 2.9.18 and USP <601>; impurity control follows ICH Q3B(R2) for low-dose degradation products, and cleanroom particle control is aligned with ISO 14644-1:2015 Class 8 at powder dispensing and filling suites. Hard hydroxypropyl methylcellulose capsules are sealed in cold-form aluminium/aluminium blisters after filling to limit moisture ingress. The terminal finished dosage types are hard capsules for dry powder inhalation in 75 µg, 150 µg, and 300 µg strengths for use with a capsule-based passive dry powder inhaler.

What Process Window Prevents Segregation in Indacaterol–Glycopyrronium Binary API Blends?

Fixed-dose LABA/LAMA capsule manufacture introduces a second cohesive micronized active, glycopyrronium bromide, into the lactose carrier system at 50 µg per capsule, corresponding to 0.20% w/w in a 25 mg fill, while indacaterol maleate contributes 110 µg or 0.44% w/w. The principal batch rejection mode is not chemical degradation but electrostatic adhesion of the two micronized actives to stainless steel contact surfaces and subsequent segregation during transfer from blender to filler hopper. To control this, each API is separately pre-blended with inhalation-grade lactose fines at 5–15% w/w of the total carrier mass before the two pre-blends are combined in a low-shear tumble blender at 15–25 rpm. An intermediate screen with 355 µm aperture is inserted after pre-blending because the glycopyrronium bromide particles form dry aggregates that survive ordinary blending if not disrupted before final dilution. Ambient relative humidity is held below 40% to reduce triboelectric charging, and polymer contact liners on transfer chutes are specified to minimize metal-API adhesion. Blend uniformity sampling follows 21 CFR 211.110 with stratified sampling at the blender discharge, and finished capsule content uniformity is assessed under Ph. Eur. 2.9.40; aerodynamic particle size distribution is verified by cascade impaction under Ph. Eur. 2.9.18 and USP <601>. The downstream process is staged as follows: dual micronization, separate pre-blends with fine lactose, low-shear final mixing, 355 µm screening, dosator capsule filling at 25 mg target fill mass, and cold-form alu-alu blister sealing. The terminal finished product type is the indacaterol maleate–glycopyrronium bromide dry powder inhalation hard capsule in a 110/50 µg fixed-dose combination for maintenance treatment of chronic obstructive pulmonary disease.

When Indacaterol Acetate Is Co-Processed with Mometasone Furoate for Once-Daily Asthma DPI Capsules

Co-formulation with the inhaled corticosteroid mometasone furoate creates three dose configurations: 150/80 µg, 150/160 µg, and 150/320 µg per capsule. In a 25 mg fill, indacaterol acetate contributes 0.60% w/w, while mometasone furoate spans 0.32% w/w, 0.64% w/w, and 1.28% w/w; this range places the mometasone component at the upper limit of what can be reliably distributed in a lactose carrier without excessive fine-particle agglomeration. The two APIs are not co-micronized in a single jet mill pass because differences in surface energy and fracture mechanics would compromise particle size distribution of the corticosteroid; instead, indacaterol acetate is pre-blended with a first lactose fines fraction, mometasone furoate is pre-blended with a second lactose fines fraction, and the two intermediate powders are combined in staged addition to the coarse α-lactose monohydrate carrier. Aerodynamic performance is tested by cascade impaction at 60 L/min under Ph. Eur. 2.9.18, and elemental impurities are controlled to inhalation-route permitted daily exposures under ICH Q3D. Degradation product and residual solvent limits follow ICH Q3B(R2) and ICH Q3C, respectively. Dosator capsule fillers are operated at 25 mg target fill weight with periodic weight checks at 10–15 min intervals to ensure low-strength mometasone configurations do not drift above the 5% weight tolerance. The terminal finished dosage types are indacaterol acetate–mometasone furoate dry powder inhalation hard capsules in 150/80 µg, 150/160 µg, and 150/320 µg strengths for once-daily asthma maintenance via a capsule-based dry powder inhaler.

Lactose carrier selection for indacaterol dry powder inhalation systems is governed by particle size distribution control rather than chemical compatibility, because the API comprises less than 2% w/w of the formulation and the carrier surface dominates interparticulate forces during capsule emptying. Inhalation-grade α-lactose monohydrate is characterized by laser diffraction under Ph. Eur. 2.9.31 and ISO 13320:2020; coarse carrier fractions typically exhibit d50 values of 90–250 µm, whereas the decisive fine lactose fraction has d50 ≤ 10 µm. The inclusion of fine lactose at 5–15% w/w of carrier mass is the primary formulation lever for raising indacaterol fine particle fraction without increasing API content. Below 5% w/w fines, low-dose blends segregate during vacuum transfer and capsule filling; above 15% w/w fines, emitted dose variability is amplified because excessively fine carriers alter powder bed cohesion and device retention. For a 25 mg fill with indacaterol addition of 0.30–1.20% w/w, the carrier must be stored below 30% RH before blending to prevent surface hydration from increasing adhesion to the capsule wall. The downstream process includes air-jet screening of lactose through a 150 µm sieve, tumble blending at 10–25 rpm, and aerodynamic verification on a Next Generation Impactor at 60 L/min in accordance with Ph. Eur. 2.9.18. The terminal produced systems are carrier-based DPI capsule powder mixtures intended for both single-agent indacaterol hard capsules and fixed-dose combination dry powder inhalation capsules.

During commercial filling of low-dose indacaterol capsule blends, the greatest batch-to-batch variance arises from static charge accumulation on dosator pins and hydroxypropyl methylcellulose capsule walls rather than from chemical degradation of the API. The fill weight remains 25 mg across strengths, while indacaterol content ranges from 0.30% w/w to 1.20% w/w; this makes blend uniformity verification under 21 CFR 211.110 and Ph. Eur. 2.9.40 the central control point. Near-infrared diffuse reflectance probes positioned at the blender discharge and at the capsule filler hopper provide real-time monitoring; calibration models for the 0.30% w/w blend target a relative standard deviation ≤ 5.0%, while the 1.20% w/w blend is controlled to ≤ 4.0%. Capsule filling is performed on dosator-type machines with low compression force on the powder plug and reduced fill speed relative to oral solid dosage applications to avoid compacting lactose carrier into dense aggregates that resist dispersion in the inhaler device. The in-process sampling plan includes stratified grab samples at 10–30 points across the blend and periodic finished capsule content uniformity testing during the filling campaign. The terminal finished product is a PAT-verified hard capsule dosage form for dry powder inhalation, with process capability indices maintained at Cpk ≥ 1.33 across three consecutive validation batches. Published commercial data for injectable liquid indacaterol and swallowed oral granule or tablet configurations remain limited; therefore those downstream routes are not included as established application sectors for this pharmaceutical-grade API.